|
[1]
|
Leijssen, L.G.J., Dinaux, A.M., Taylor, M.S., Deshpande, V., Hiroko, K., Bordeianou, L.G., et al. (2019) Perineural Invasion Is a Prognostic but Not a Predictive Factor in Nonmetastatic Colon Cancer. Diseases of the Colon & Rectum, 62, 1212-1221. [Google Scholar] [CrossRef]
|
|
[2]
|
魏哲威, 张常华, 余捷, 吴菁, 何裕隆. 含奥沙利铂辅助化疗方案治疗结直肠癌可切除肝转移的预后分析[J]. 热带医学杂志, 2018, 18(9): 1156-1159, 1181.
|
|
[3]
|
Ouyang, M., Luo, Z., Wu, J., Zhang, W., Tang, S., Lu, Y., et al. (2019) Comparison of Outcomes of Complete Mesocolic Excision with Conventional Radical Resection Performed by Laparoscopic Approach for Right Colon Cancer. Cancer Management and Research s, 25, 8647-8656. [Google Scholar] [CrossRef]
|
|
[4]
|
吴福红, 孙元珏. XELOX与FOLFOX4方案治疗晚期结直肠癌的临床研究[J]. 医学信息(下旬刊), 2011, 24(18): 3-5.
|
|
[5]
|
徐俊, 陈旭. 结肠癌辅助化疗的研究进展[J]. 医学综述, 2017, 23(20): 4039-4044.
|
|
[6]
|
徐瑞华, 邱妙珍. 晚期结直肠癌化疗的研究进展[J]. 癌症, 2008, 27(6): 661-666.
|
|
[7]
|
Wang, D. and Fu, J. (2014) Symptom Clusters and Quality of Life in China Patients with Lung Cancer Undergoing Chemotherapy. African Health Sciences, 14, 49-55. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
郭兴罡, 赵智辅, 陈杰, 庄海英. 顺铂化疗过程中联合应用大剂量止吐药预防胃肠道反应[J]. 黑龙江医学, 2000(4): 30.
|
|
[9]
|
林万隆, 陈强. 奥沙利铂的药理作用及临床应用[J]. 中国肿瘤临床, 2000, 27(11): 872-874.
|
|
[10]
|
潘建军. 肿瘤放化疗所引起腹泻两种治疗方法比较分析[J]. 求医问药(下半月), 2011, 9(11): 563.
|
|
[11]
|
朱一玢. 时辰化疗结合择时用药缓解肠癌术后化疗胃肠反应的研究[D]: [硕士学位论文]. 广州: 广州中医药大学, 2013.
|
|
[12]
|
曹迪, 张亚密, 全建峰. 中医药改善化疗毒副反应的研究进展[J]. 中国中医急症, 2020, 29(7): 1302-1305, 1308.
|
|
[13]
|
Kumamoto, K., Nakachi, Y., Mizuno, Y., Yokoyama, M., Ishibashi, K., Kosugi, C., et al. (2019) Expressions of 10 Genes as Candidate Predictors of Recurrence in Stage Ⅲ Colon Cancer Patients Receiving Adjuvant Oxaliplatin-Based Chemotherapy. Oncology Letters, 18, 1388-1394. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
徐萌, 王勇, 张梅, 胡金鹏, 李平. Ⅲ期结肠癌术后辅助化疗联合中药治疗的疗效研究[J]. 安徽医学, 2020, 41(3): 273-276.
|
|
[15]
|
林胜友, 沈敏鹤, 舒静娜, 蓝继. 780例大肠癌中医证型分类 特征的回顾性分析[J]. 浙江中医药大学学报, 2011, 35(3): 322-324.
|
|
[16]
|
侯风刚, 岑怡, 贯剑, 朱凌云, 殷晓聆, 刘静. 肠癌中医症状证候临床调查分析[J]. 辽宁中医药大学学报, 2010, 12(1): 32-34.
|
|
[17]
|
Xu, S.Z. (2014) Clinical Study on Chemotherapy Induced Diarrhea in Colorectal cancer Patients. Zhejiang University, Hangzhou.
|
|
[18]
|
梅丹, 陆俊国, 顾海娟, 郭小红, 徐艳艳, 倪美鑫. 伊立替康化疗相关性腹泻发生的特点与危险因素分析[J]. 中国医院药学杂志, 2019, 39(2): 191-195.
|
|
[19]
|
Andreyev, J., Ross, P., Donnellan, C., Lennan, E., Leonard, P., Waters, C., et al. (2014) Guidance on the Management of Diarrhoea during Cancer Chemotherapy. The Lancet Oncology, 15, e447-e460. [Google Scholar] [CrossRef]
|
|
[20]
|
Yu, Q.Y., Wang, H.L., Wu, T., et al. (2012) A Case of Serious Adverse Effect Induced by Irinotecan. Chinese Journal of Pharmaceuticals, 32, 733-735.
|
|
[21]
|
张宇涛. 结直肠癌的治疗进展[J]. 山西医药杂志, 2020, 49(5): 535-536.
|
|
[22]
|
Levi, F. (1999) Caner Chronotherapy. Journal of Pharmacy and Pharmacology, 51, 891-898. [Google Scholar] [CrossRef] [PubMed]
|